ADMS Stock Performance, Insider Transaction and News

ADMS - Adamas Pharmaceuticals, Inc.

Market Cap	376.37M	P/E	-	EPS this Y	49.30%	Ern Qtrly Grth	-
Income	-62.71M	Forward P/E	-22.22	EPS next Y	64.10%	50D Avg Chg	17.00%
Sales	88.19M	PEG	0.09	EPS past 5Y	-	200D Avg Chg	48.00%
Dividend	N/A	Price/Book	N/A	EPS next 5Y	-90.30%	52W High Chg	-10.00%
Recommedations	3.00	Quick Ratio	3.91	Shares Outstanding	45.79M	52W Low Chg	104.00%
Insider Own	0.71%	ROA	-15.40%	Shares Float	29.69M	Beta	2.82
Inst Own	79.35%	ROE	-	Shares Shorted/Prior	477.29K/1.60M	Price	8.22
Gross Margin	97.64%	Profit Margin	-71.11%	Avg. Volume	1,317,311	Target Price	8.52
Oper. Margin	-38.66%	Earnings Date	Feb 21	Volume	3,151,400	Change	0.00%

Healthcare | Drug Manufacturers | United States

About Adamas Pharmaceuticals, Inc.

Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. It offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications, as well as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes; and OSMOLEX ER, an extended release tablet to treat Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. The company is also developing ADS-4101, which has completed two Phase 1b studies for treating partial onset seizures in patients with epilepsy. In addition, it offers NAMZARIC and NAMENDA XR, a memantine hydrochloride extended release and donepezil hydrochloride capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. As of November 24, 2021, Adamas Pharmaceuticals, Inc. operates as a subsidiary of Supernus Pharmaceuticals, Inc.

ADMS Chatroom

11thestate Posted - 1 week ago

ca_rott1487 Posted - 3 weeks ago

$ADMS has agreed to settle $4.65M with investors to resolve claims regarding the overstatement of their lead product's prospects. Claim submission info and details: https://11thestate.com/cases/adamas-shareholder-settlement Who is eligible to get a payout? All persons and entities that purchased or otherwise acquired the publicly traded common stock of Adamas, between August 8, 2017 and March 4, 2019, both dates inclusive, and were damaged thereby.

Stan_Vick Posted - 1 month ago

Adamas was acquired by $SUPN in 2021. How do investors in $ADMS find out about settlement entitled to them? @11thestate

Stan_Vick Posted - 1 month ago

🎉 Adamas Pharma agreed to settle $4.65 million with investors to resolve claims for the overstatement of $ADMS lead product's prospects => https://11thestate.com/cases/adamas-shareholder-settlement

ca_rott1487 Posted - 1 month ago

$SUPN $ADMS has agreed to settle $4.65M to resolve claims regarding the overstatement of their lead product's prospects. case page: https://11thestate.com/cases/adamas-shareholder-settlement

Eugene_O Posted - 5 months ago

$SUPN Anyone watching this for the CVR's from the Nov 2021 merger with $ADMS ?

Happy_Analyzer Posted - 8 months ago

$LIXT wow, good job shorty $ADMS $MSGM still on watch

risenhoover Posted - 03/26/23

$ADMS ADMS / Adamas Pharmaceuticals Inc Price Target Updated https://fintel.io/sfo/us/adms?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget

risenhoover Posted - 03/25/23

$ADMS ADMS / Adamas Pharmaceuticals Inc Price Target Updated https://fintel.io/sfo/us/adms?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=pricetarget